This site is intended for healthcare professionals
CSU Learning Zone
Declaration of sponsorship Novartis Pharma AG

Primary Care

Declaration of sponsorship Novartis Pharma AG
Read time: 60 mins

Primary Care Focus

 

We know that as a GP, it can be difficult to maintain a working knowledge of multiple conditions. We’ve developed this practical guide making it easier for you to read up on the definitions of allergy, autoimmunity and urticaria.

 

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

References

Cetirizine hydrochloride Summary of Product Characteristics. 2017. Available at www.medicines.org.uk/emc/medicine/29498.

Desloratadine Summary of Product Characteristics. 2016. Available at https://www.medicines.org.uk/emc/product/4888/smpc.

EAACI/GA2LEN/EDF WAO guidelines for chronic spontaneous urticaria. 2017 update: in press.

Ebastine Summary of Product Characteristics. Available at https://mri.cts-mrp.eu/download/DE_H_0742_002_FinalSPC_1of2.pdf.

Fexofenadine Summary of Product Characteristics. 2014. Available at https://www.medicines.org.uk/emc/product/3488/smpc.

Godse KV. Indian J Dermatol 2009; 54(4):310–2.

González-Núñez V et al. Expert Opin Drug Saf 2016; 15:1439–48.

Ilaxten Summary of Product Characteristics. 2017. Available at www.medicines.org.uk/emc/medicine/24461.

Johansson SG et al. J Allergy Clin Immunol 2003; 113(5):832–6.

Kaplan AP. Allergy Asthma Immunol Res 2012; 4(6):326–31.

Kathuria PC. Indian J Allergy Asthma Immunol 2011; 25(1):33–7.

Kolkhir P et al. J Allergy Clin Immunol 2017; 139(6):1772–81.

Lapi F et al. British Journal of Dermatology 2016; 174:996–1004.

Levocetirizine dihydrochloride Summary of Product Characteristics. 2011. Available at https://www.medicines.org.uk/emc/product/5927/smpc.

Loratadine Summary of Product Characteristics. 2018. Available at https://www.medicines.org.uk/emc/product/4501/smpc.

Maurer M et al. Allergy 2011; 66(3):317–30.

Maurer M et al. Allergy 2017; 72(12):2005–16.

Maurer M et al. J Dtsch Dermatol Ges 2013; 11(10):971–7.

Mizollen Summary of Product Characteristics. 2018. Available at https://www.medicines.org.uk/emc/product/363/smpc.

Mullol J et al. Allergy 2015; 70 (Suppl 100):1–24.

Pawankar R et al. World Allergy Organization, White Book on Allergy, 2011.

Rupatadine Summary of Product Characteristics. 2017. Available at https://www.medicines.org.uk/emc/product/2501/smpc.

Waljee AK et al. BMJ 2017;357:j1415.

Zuberbier T et al. Allergy 2018 Jul;73(7):1398–414.

Developed by EPG Health for Medthority in collaboration with Novartis Pharma AG and J. Uriach y Compañía S.A, with some content provided by Novartis Pharma AG and J. Uriach y Compañía S.A. The views presented in the videos are those of the presenters and not necessarily those of the industry sponsor, Novartis Pharma AG. Any data on non- Novartis products are based on publicly available information at the time of content update. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the SmPC or product information approved in your local country.